CD22


Also found in: Wikipedia.

CD22

a type I transmembrane protein found in the cytoplasm of pre-B cells and on the surface of mature B cells that facilitates signal transduction; expressed in patients with hairy cell leukemias and in some with B-cell lymphomas.
References in periodicals archive ?
Flow cytometry showed a 96% variable size, clonal B cell population expressing CD10, CD11c, CD19, CD20, CD22, CD45, CD52, CD103, CD123, BCL2, and Kappa.
has entered into an agreement to obtain a license for the company's CAR-T cell product candidate targeting CD22, a protein expressed on most B cell leukemias and lymphomas.
CD3, CD4, CD9, CD11, CD19, CD20, CD22, CD26, CD27, CD28, CD29, CD33, CD37, CD40, CD44, CD45, CD47, CD52u CD55, CD56, CD66, CD70, CD74, CD80, CD95, CD98, CD100, CD117, CD135, CD137, CD152, CD200, CD223, CD227, CD246, CD248, CD274, CD276, CD279
6,17,18) EBV-positive DLBCL of the elderly will express at least some Bcell markers (CD19, CD20, CD22, CD79a, PAX-5), as well as IRF4/MUM-1.
In addition to targeting CD20, we are studying a humanized antibody (less mouse protein) against CD22, another marker for NHL, labeled with [sup.
III] specific A kinase (PRKA) anchor AKAP5 Signal transduction protein 5 Ataxin 1 ATXN1 RNA binding CD22 antigen CD22 Cell adhesion Connective tissue CTGF Regulation of cell growth factor growth, cell adhesion RNA, U70 small nucleolar RNU70 Unknown Integrin beta 1 binding ITGB1BP1 Cell adhesion protein 1 E2F transcription E2F1 [G.
epratuzumab, AMG CD22 is commonly expressed by B-cell 412) malignant cells.
In a related development, the company announced that near-term clinical development plans now include the further evaluation of two proprietary cancer therapeutics, its humanized CD22 antibody (IMMU-103) and its CD20 antibody (IMMU-106), in each case for patients with certain autoimmune diseases.
He and his colleagues designed BL22 as a so-called fusion protein that combines a toxin with an antibody that attaches to the CD22 molecule.
Hairy cells will often demonstrate bright CD22 and CD11c co-expression and segregate out as a distinct population on two-color flow cytometric analysis.
New (Research Collaboration) -- Inhibition of B Cell Activation and Plasma Cell Differentiation by Epratuzumab, a Humanized Monoclonal Antibody Targeting CD22
CD19, CD22, CD25, CD30, CD33 and others are being investigated.